| Long name: |
FITC Conjugated, CPLX1 Polyclonal Antibody |
| Category: |
Conjugated Primary Antibodies |
| Conjugation: |
Anti-FITC Antibody |
| Host Organism: |
Rabbit (Oryctolagus cuniculus) |
| Target Antigen: |
CPLX1 |
| Specificity: |
This is a highly specific antibody against CPLX1 |
| Modification: |
Unmodified |
| Modification site: |
None |
| Clonality: |
Polyclonal |
| Clone: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Source: |
KLH conjugated synthetic peptide derived from human CPLX1 |
| Tested applications: |
IF(IHC-P) |
| Recommended dilutions: |
IF(IHC-P)(1:50-200) |
| Crossreactivity: |
Mouse, Rat, Human |
| Crossreactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Antigen background: |
A progressive loss of Complexin 2 occurs in the brains of mice carrying the Huntington disease mutation, Changes in the neurotransmitter release might contribute to the motor, Complexin 1 and Complexin 2 are expressed in presynaptic terminals of inhibitory and excitatory hippocampal neurons, Complexin 2 may play a role in LTP (long term potentiation) following tetanic stimulation, Complexins are important regulators of transmitter release at a late step in calcium dependent neurotransmitter release or immediately after the calcium-triggering step of fast synchronous transmitter release and preceding vesicle fusion, Complexins promote SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) precomplex formation by binding to synaxin with its a-helical domain, Neurons lacking complexins show reduced transmitter release efficiency due to decreased calcium sensitivity of the synaptic secretion process, also designated Synaphin 1 and Synaphin 2, an autosomal dominant neurodegenerative disorder, and in cytoplasmic pools during early stages of development, contain an a-helical middle domain of approximately 58 amino acids, emotional and cognitive dysfunctions seen in these mice, respectively, Complexin 1 and Complexin 2 |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store refrigerated at 2 to 8 degrees Celcius for up to 1 year, 09% sodium azide, Keep the antibody in an aqueous buffered solution containing 1% BSA |
| Excitation Emission: |
494nm/518nm |
| Synonyms: |
CPX-I |
| Properties: |
Bioss Primary Conjugated Antibodies FITC is highly sensitive to pH extremes, FITC has a green emission that's usually collected at 530 nanometers, FITC has a high quantum yield (efficiency of energy transfer from absorption to emission fluorescence) and approximately half of the absorbed photons are emitted as fluorescent light, For fluorescent microscopy applications, This Bioss Primary Conjugated Antibodies Fluorescein isothiocyanate (FITC) antibody is currently after some BD antibodies the most commonly used fluorescent dye for FACS, When excited at 488 nanometers, its photo bleaching effects are not observed due to a very brief interaction at the laser intercept, the 1 FITC is seldom used as it photo bleaches rather quickly though in flow cytometry applications, the FL1 detector of a FACSCalibur or FACScan, C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
CPLX1 Conjugated |
| Short name: |
FITC Conjugated, CPLX1 Antibody |
| Technique: |
Fluorescein, antibodies against human proteins, antibodies for, antibody Conjugates, Antibody |
| Label: |
FITC |
| Alternative name: |
fluorecein coupled, complexin 1 (Antibody to) |
| Alternative technique: |
antibodies |
| Alternative to gene target: |
CPLX1 and IDBG-6120 and ENSG00000168993 and 10815, CPX-I and CPX1, Cplx1 and IDBG-188148 and ENSMUSG00000033615 and 12889, Cytoplasm, syntaxin binding, this GO :0000149 and SNARE binding and molecular function this GO :0005326 and neurotransmitter transporter activity and molecular function this GO :0005829 and cytosol and cellular component this GO :0006836 and neurotransmitter transport and biological process this GO :0006887 and exocytosis and biological process this GO :0007268 and synaptic transmission and biological process this GO :0007269 and neurotransmitter secretion and biological process this GO :0014047 and glutamate secretion and biological process this GO :0016079 and synaptic vesicle exocytosis and biological process this GO :0017075 and syntaxin-1 binding and molecular function this GO :0019905 and syntaxin binding and molecular function this GO :0030073 and insulin secretion and biological process this GO :0030425 and dendrite and cellular component this GO :0031201 and SNARE complex and cellular component this GO :0043025 and neuronal cell body and cellular component this GO :0043234 and protein complex and cellular component this GO :0045202 and synapse and cellular component this GO :0070032 and synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex and cellular component, this GO :0000149 : SNARE binding, this GO :0000149 : SNARE binding and also this GO :0005326 : neurotransmitter transporter activity and also this GO :0017075 : syntaxin-1 binding and also this GO :0019905 : syntaxin binding, this GO :0005326 : neurotransmitter transporter activity, this GO :0017075 : syntaxin-1 binding, this GO :0019905 : syntaxin binding, complexin 1 |
| Identity: |
2309 |
| Gene: |
CPLX1 |
More about : CPLX1 |
| Long gene name: |
complexin 1 |
| Locus: |
4p16, 3 |
| Discovery year: |
1999-09-09 |
| GenBank acession: |
AF022383 |
| Entrez gene record: |
10815 |
| Pubmed identfication: |
7553862 |
| Havana BLAST/BLAT: |
OTTHUMG00000160005 |